Technical Analysis for COCP - Cocrystal Pharma, Inc.

Grade Last Price % Change Price Change
grade F 0.61 -1.61% -0.01
COCP closed down 1.61 percent on Monday, November 11, 2019, on 2.62 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical COCP trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -1.61%
Volume Surge Other -1.61%
Calm After Storm Range Contraction -1.61%
New 52 Week Low Weakness -1.61%
Wide Bands Range Expansion -1.61%

Older signals for COCP ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Medicine Biotechnology Biology Influenza Microbiology Antiviral Drug Virus HCV Biocides Influenza Viruses
Is COCP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.28
52 Week Low 0.6
Average Volume 56,464
200-Day Moving Average 2.2588
50-Day Moving Average 1.5253
20-Day Moving Average 0.9878
10-Day Moving Average 0.777
Average True Range 0.1335
ADX 59.43
+DI 5.7051
-DI 40.5405
Chandelier Exit (Long, 3 ATRs ) 1.1095
Chandelier Exit (Short, 3 ATRs ) 1.0005
Upper Bollinger Band 1.5125
Lower Bollinger Band 0.4631
Percent B (%b) 0.14
BandWidth 106.23608
MACD Line -0.2723
MACD Signal Line -0.2595
MACD Histogram -0.0128
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.73
Resistance 3 (R3) 0.74 0.72 0.71
Resistance 2 (R2) 0.72 0.69 0.71 0.70
Resistance 1 (R1) 0.66 0.67 0.65 0.65 0.70
Pivot Point 0.64 0.64 0.63 0.63 0.64
Support 1 (S1) 0.58 0.61 0.57 0.57 0.52
Support 2 (S2) 0.56 0.59 0.55 0.52
Support 3 (S3) 0.50 0.56 0.51
Support 4 (S4) 0.49